FORM D

g685

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

RECD S.E.C. SEP 1 8 2007 1086

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR**

UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL

OMB Number: 3235-0076

Expires: April 30, 2008 Estimated average burden

hours per response...... 16.00

SEC USE ONLY					
Prefix	Serial				
DATE R	ECEIVED				
1	1				

Name of Offering (check if this is an amendment and name has changed, and indicates Research Pharmaceutical Services. Inc.	ate change.)
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Type of Filing: New Filing Amendment	Section 4(6) ULOE
A. BASIC IDENTIFICA	ATION DATA
1. Enter the information requested about the issuer	07078147
Name of Issuer (check if this is an amendment and name has changed, and indicate Research Pharmaceutical Services, Inc.	
Address of Executive Offices (Number and Street, City, State, 2 520 Virginia Drive, Fort Washington, PA 19034	Cip Code) Telephone Number (Including Area Code) (215) 540-0700
Address of Principal Business Operations (Number and Street, City, State, 2 (if different from Executive Offices)	Telephone Number (Including Acc Code)
Brief Description of Business Provider of clinical research services.	SEP 2 4 2007
Type of Business Organization	other (please specify) FINANCIAL
Actual or Estimated Date of Incorporation or Organization: Month Ye	6 🛮 Actual 🗆 Estimated
CN for Canada; FN for other foreig	n jurisdiction)
CENED AL INCUDITORIO	

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTIO	N
----------	---

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

	A. BA	ASIC IDENTIFICATIO	N DATA	
Enter the information requested for Each promoter of the issuer, i Each beneficial owner having Each executive officer and dir Each general and managing page.	the following: f the issuer has been organize the power to vote or dispose, rector of corporate issuers and	d within the past five year or direct the vote or disp	rs; osition of, 10% o	or more of a class of equity securities of the issuer; ers of partnership issuers; and
Check Box(es) that Apply: Promot	er Beneficial Owner		□ Director	General Partner
Full Name (Last name first, if individua Koffer, Harris	1)			
Business or Residence Address (Numl c/o Research Pharmaceutical Services		•	19034	
Check Box(es) that Apply: Promot	er Beneficial Owner	Executive Officer	Director	General Partner
Full Name (Last name first, if individua Bell, Steven	l)			
Business or Residence Address (Numl c/o Research Pharmaceutical Services,	· · · · · · · · · · · · · · · · · · ·		19034	
Check Box(es) that Apply: Promot	er Beneficial Owner	Executive Officer	□ Director	☐ Managing Member
Full Name (Last name first, if individual Pertman, Daniel	l)			
Business or Residence Address (Number of Research Pharmaceutical Services,		•	19034	
Check Box(es) that Apply: Promot	er Beneficial Owner	Executive Officer	□ Director	☐ Managing Member
Full Name (Last name first, if individua Raynor, Daniel)			
Business or Residence Address (Number of Research Pharmaceutical Services,		•	19034	
Check Box(es) that Apply: Promot	er 🔲 Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, if individual Macdonald, James	()			
Business or Residence Address (Numb c/o Research Pharmaceutical Services,		,	19034	
Check Box(es) that Apply:	er Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual Smith, Dennis	()			
Business or Residence Address (Numb c/o Research Pharmaceutical Services,		•	19034	
Check Box(es) that Apply:	er 🔲 Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, if individual Yang, Edward)		. ————	
Business or Residence Address (Numb c/o Research Pharmaceutical Services,	•	•	19034	
Check Box(es) that Apply: Promot	er Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, if individual)		· · -	

Business or Residence Address (Number and Street, City, State, Zip Code)

Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first,	if individual)					
Business or Residence Add	ress (Number	and Street, City, State, Zip	Code)			
		(Hee blank sheet or conv	and use additional conjes	of this sheet as	necessary)	

					B. INFORM	ATION ABO	OUT OFFER	RING				
L											Yes	No No
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?									\boxtimes			
Answer also in Appendix, Column 2, if filing under ULOE.								Nat ==="	enhlo			
2. What is the minimum investment that will be accepted from any individual?								Not appli				
							options					
3. Does t	the offering p	ermit joint o	wnership of a	single unit?								No
												\boxtimes
remun person than fi dealer	eration for so or agent of ive (5) perso only. No	olicitation of a broker or d ns to be listed t Applicable	purchasers in ealer register d are associat	onnection ed with the S	with sales of SEC and/or w	securities in ith a state or	the offering, states, list th	If a person t e name of the	o be listed is broker or de	sion or similar an associated ealer. If more that broker or] :	
ruii Name	e (Last name	first, if indiv	iduai)									
Business of	or Residence	Address (Nu	mber and Str	eet, City, Sta	ite, Zip Code))						
Name of A	Associated B	roker or Deal	ег									
					icit Purchaser	rs	.					
	_		idual States).									. All States
□ AL	□ AK □ IN	□ AZ □ IA	∐ AR □ KS	□ CA □ KY	□ CO □ LA	□ CT □ ME	☐ DE ☐ MD	∐ DC □ MA	∏ FL □ MI	□ GA □ MN	∐ HI □ MS	□ ID □ MO
☐ MT	☐ NE	□ NA □ IV	☐ NH	□ NJ	□ NM	NY	□ NC	□ ND	□ _{OH}	OK	OR	□ PA
□RI	□ sc	□ SD	☐ TN	□TX	UT	☐ VT	□ VA	□WA	□WV	□wi	□WY	☐ PR
Full Name	: (Last name	first, if indiv	idual)									
Business of	or Residence	Address (Nu	mber and Str	eet, City, Sta	te, Zip Code))			-,-	•		
Name of A	Associated B	roker or Deal	er									
					icit Purchases	rs						
			ridual States).							— - ·		All States
□ AL □ IL	□ AK □ IN	□ AZ □ IA	□ AR □ KS	□ CA □ KY	□ CO □ LA	☐ CT ☐ ME	☐ DE ☐ MD	☐ DC ☐ MA	□ FL □ MI	□ GA □ MN	∐ HI ∐ MS	□ ID □ MO
\square MT	☐ NE	□NV	□ №	□ NJ	□ NM	□ NY	□ NC	□ ND	□он	🗆 ок	☐ OR	☐ PA
□RI	□ sc	□ SD	☐ TN	☐ TX	UT [TV 🗌	□ VA	□WA	□wv	□ WI	□WY	□ PR
Full Name	(Last name	first, if indiv	idual)							<u></u>		·
	- ·											
Business or Residence Address (Number and Street, City, State, Zip Code)												
Name of A	Associated B	roker or Deal	er									
					icit Purchaser	rs						5
(Check "	All States" o	r check indiv	ridual States). ☐ AR	□ CA	co		☐ DE	□ DC	☐ FL	□GA	□ ні	. ☐ All States ☐ ID
	□ IN		☐ KS	□ CA □ KY	□rv □co	□ CT □ ME	☐ MD	□ MA	□ MI	□ GA □ MN	MS	□ MO
□ мт	□ NE	□ NV	☐ NH	□ил	□ мм	אין 🔲 אין	□ NC	םא □	□он	□ ок	OR	□ PA
□ RI	□ SC	□ SD	∐TN	☐ TX	UT	□ VT	□ VA	□ WA	□wv	□ WI	□ WY	☐ PR

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box 🔲 and indicate in the columns below the amounts of the securities offered for exchange and already exchanged, Amount Already Aggregate Type of Security Offering Price Sold Debt Equity Common Preferred Convertible Securities (including warrants) Partnership Interests. Other (Specify: Common Stock Option)..... <u>\$0</u> · <u>\$0</u> Answer also in Appendix, Column 3, if filing under ULOE. 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Aggregate Number Dollar Amount of Purchases Investors Accredited Investors \$0 Non-accredited Investors Total (for filings under Rule 504 only) \$0 Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of Dollar Amount Type of offering Security Sold Rule 505 Regulation A a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box

to the left of the estimate. Transfer Agent's Fees Printing and Engraving Costs Legal Fees X \$5,000 Accounting Fees Engineering Fees. Sales Commissions (specify finders' fees separately) Other Expenses (identify) _ Total \$5,000

putposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

		Payments to Officers, Directors, & Affiliates	Payments to Others
Salaries and fees		<u>\$0</u>	<u>\$0</u>
Purchase of real estate		<u>\$0</u>	<u>\$0</u>
Purchase, rental or leasing and installation	of machinery and equipment	<u>\$0</u>	<u>\$0</u>
Construction or leasing of plant buildings	and facilities	<u>\$0</u>	<u>\$0</u>
Acquisition of other business (including the offering that may be used in exchange for issuer pursuant to a merger)		<u>\$0</u>	<u>\$0</u>
Repayment of indebtedness		<u>\$0</u>	<u>\$0</u>
Working capital, acquisitions, and reserve	S	<u>\$0</u>	<u>\$0</u>
Other (specify):			
Column Totals		<u>\$0.</u> <u>\$0</u>	<u>\$0</u> <u>\$0</u>
Total Payments Listed (column totals add	ed)	···········	<u>\$0</u>
	D. FEDERAL SIGNATURE		
	by the undersigned duly authorized person. If this notice . Securities and Exchange Commission, upon written req (b)(2) of Rule 502.		
Issuer (Print or Type)	Signature	Date	
Research Pharmaceutical Services, Inc		_ 9/1	O , 2007
Name of Signer (Print or Type) STRUEN BEW	Title of Signer (Print or Type)		
-			· · · ·

A	T	ГГ	N	ri.	N

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

E. STATE SIGNATURE

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)

Research Pharmaceutical Services, Inc.

Signature /

Date 9/10 , 200'

Name of Signer (Print or Type)	_	Title of Signer (Print or Type)	\sim	
STEUEN	BELL		CPO	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

